Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 3/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
| ▸ | CCNC | P24863 | 4/20 | 0.46 |
| ▸ | CDK8 | P49336 | 4/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | ITK | Q08881 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25402169 | 0.85 | HDAC6 (0.46) | HDAC8HDAC6HDAC2 | |
| SCHEMBL27061741 | 0.84 | TP53 (0.47) | SMN1; SMN2HPGDSHPGD | |
| SCHEMBL25753506 | 0.83 | MAPT (0.50) | SMN1; SMN2HPGDSCHEK2 | |
| SCHEMBL21730148 | 0.82 | KDM4E (0.50) | TDP1SMN1; SMN2HPGDHTT | |
| SCHEMBL25401469 | 0.80 | TDP1 (0.53) | THRBTDP1SMN1; SMN2HPGDHTT | |
| SCHEMBL17112019 | 0.79 | RAB9A (0.56) | PLAUSMN1; SMN2HPGDHTTHDAC8 | |
| SCHEMBL1725437 | 0.78 | LCK (0.46) | HPGDSMMP13CHEK2 | |
| Hydrochloric Acid SCHEMBL31386777 | 0.77 | LCK (0.44) | HPGDSMMP13CHEK2 | |
| SCHEMBL9989116 | 0.76 | NPC1 (0.60) | SMN1; SMN2HPGDSHTT | |
| SCHEMBL27062550 | 0.75 | ALDH1A1 (0.34) | TDP1SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023220440-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023091644-A2 | HSD17B13-RELATED DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-05-25 | — | — | WO | disclosed |
| WO-2022099159-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2022-05-12 | — | — | WO | disclosed |
| WO-2021234459-A9 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2022-02-03 | — | — | WO | disclosed |
| WO-2021234459-A2 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2021-11-25 | — | — | WO | disclosed |
| WO-2021237223-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2021-11-25 | — | — | WO | disclosed |
| US-20110319379-A1 | Substituted Indazole Amides And Their Use As Glucokinase Activators | CORBETT JEFFREY W (US) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319379-A1 | Substituted Indazole Amides And Their Use As Glucokinase Activators | GCKR, GCK, GALK1 | PLK1 3725/4885THRB 1701/4885PLAU 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.